Literature DB >> 8558429

Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.

M Hatch1, R W Freel, S Shahinfar, N D Vaziri.   

Abstract

Possible mechanisms for the hypouricemic effects of the angiotensin II receptor antagonist losartan were examined using rats with experimental chronic renal failure (CRF) and control animals. The results show that losartan has a uricosuric effect in rats with normal or decreased renal function. Renal clearance of urate was increased 3-fold in CRF rats and 2-fold in control rats after 7 days of intraperitoneal losartan administration. Although the results show that losartan and its metabolite EXP-3174 alter urate and Cl- transport across isolated short-circuited intestine, these agents do not promote urate secretion into the intestinal lumen. Unidirectional urate and Cl- fluxes were reduced across normal rat colon and unaltered in the small intestine in the presence of losartan. In CRF rat colon, net secretion of urate and Cl- was abolished after losartan addition at 10(-5) M. Transport across the small intestine of CRF rats did not change in the presence of a similar concentration of drug. Losartan treatment of CRF rats before the removal of colonic tissues reversed the basal net secretion of urate to net absorption. These results suggest that the changes in intestinal transport observed in the presence of losartan appear to be mediated via the angiotensin II receptor antagonistic action of this drug. Direct determination of the effects of angiotensin II on urate and Cl- transport across colonic tissues from control animals revealed a significant angiotensin II stimulation of urate secretion. These angiotensin II-induced alterations in transport were inhibitable by losartan.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558429

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Update on gout: pathophysiology and potential treatments.

Authors:  Aryeh M Abeles; Jean Y Park; Michael H Pillinger; Bruce N Cronstein
Journal:  Curr Pain Headache Rep       Date:  2007-12

Review 2.  Intestinal adaptations in chronic kidney disease and the influence of gastric bypass surgery.

Authors:  Marguerite Hatch
Journal:  Exp Physiol       Date:  2014-06-20       Impact factor: 2.969

3.  Pharmacokinetics and blood pressure response of losartan in end-stage renal disease.

Authors:  D A Sica; C E Halstenson; T W Gehr; W F Keane
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

4.  Angiotensin II involvement in adaptive enteric oxalate excretion in rats with chronic renal failure induced by hyperoxaluria.

Authors:  Marguerite Hatch; Robert W Freel
Journal:  Urol Res       Date:  2003-10-22

5.  Increased colonic sodium absorption in rats with chronic renal failure is partially mediated by AT1 receptor agonism.

Authors:  Marguerite Hatch; Robert W Freel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-06-05       Impact factor: 4.052

6.  Serum uric acid, protein intake and mortality in hemodialysis patients.

Authors:  Christina Park; Yoshitsugu Obi; Elani Streja; Connie M Rhee; Christina J Catabay; Nosratola D Vaziri; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2017-10-01       Impact factor: 5.992

7.  Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands.

Authors:  Isadora Prado Cano; Thiago José Dionisio; Tânia Mary Cestari; Adriana Maria Calvo; Bella Luna Colombini-Ishikiriama; Flávio Augusto Cardoso Faria; Walter Luiz Siqueira; Carlos Ferreira Santos
Journal:  PLoS One       Date:  2019-05-22       Impact factor: 3.240

8.  Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan.

Authors:  Sadayoshi Ito; Hiroaki Naritomi; Toshio Ogihara; Kazuyuki Shimada; Kazuaki Shimamoto; Heizo Tanaka; Nobuo Yoshiike
Journal:  Hypertens Res       Date:  2012-05-10       Impact factor: 3.872

9.  Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome.

Authors:  Anna Masajtis-Zagajewska; Jacek Majer; Michał Nowicki
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-08-25       Impact factor: 1.636

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.